NovoCure Ltd [NVCR] stock is trading at $11.39, down -0.35%. An important factor to consider is whether the stock is rising or falling in short-term value. The NVCR shares have gain 3.83% over the last week, with a monthly amount drifted -34.95%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on July 25, 2025, when Wells Fargo downgraded its rating to a Equal Weight but kept the price target unchanged to $14.50 for it. Previously, Ladenburg Thalmann started tracking the stock with Buy rating on July 08, 2025, and set its price target to $30. On December 02, 2024, upgrade upgraded it’s rating to Outperform and revised its price target to $30 on the stock. H.C. Wainwright upgraded its rating to a Buy and increased its price target to $30 on October 16, 2024. H.C. Wainwright downgraded its rating to Neutral for this stock on August 28, 2023, and downed its price target to $25. In a note dated August 08, 2023, Piper Sandler upgraded an Overweight rating on this stock but restated the target price of $45.
NovoCure Ltd [NVCR] stock has fluctuated between $10.91 and $34.13 over the past year. Currently, Wall Street analysts expect the stock to reach $14.5 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $11.39 at the most recent close of the market. An investor can expect a potential return of 27.3% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
NovoCure Ltd [NASDAQ:NVCR] reported sales of 630.16M for the trailing twelve months, which represents a growth of 5.62%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -0.27%, Pretax Profit Margin comes in at -0.23%, and Net Profit Margin reading is -0.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.48 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, NovoCure Ltd’s Current Ratio is 1.45. On the other hand, the Quick Ratio is 1.39, and the Cash Ratio is 0.2. Considering the valuation of this stock, the price to sales ratio is 2.02, the price to book ratio is 3.64.
Transactions by insiders
Recent insider trading involved Brackmann Christoph, Chief Financial Officer, that happened on Jul 29 ’25 when 20000.0 shares were purchased. Director, Stafford Kristin completed a deal on Jun 03 ’25 to sell 999.0 shares. Meanwhile, Director LEUNG GABRIEL sold 999.0 shares on Jun 03 ’25.
